CytoSorbents Corporation (CTSO)

[HadToHavit]

What is the protocol?
IF I have Covid-19 and I am admitted to the hospital due to my other health issues... I could slide into having Pneumonia... hence the ventilator needs... or the lack there of... Pneumonia? Shock!

Where does the Cytosorb column come in?

Our website … if you look hard enough... details this from DC

I can tell you that IF I were in charge.. A link to this text would be VERY PROMINENT on the website as soon as it opened.. What the hell!!

The underlying cause for these complications is often a cytokine storm that results in a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases. Steroids are being used reflexively to try to control this inflammation, despite WHO recommendations against using steroids in COVID-19 infection, and evidence from other coronavirus infections (e.g. SARS and MERS) and influenza that its use can delay viral clearance and increase mortality.
This is why CytoSorb represents a potentially promising option in helping to treat these patients, and get them out of the ICU faster, thereby relieving this bottleneck. Although CytoSorb does not kill or remove the virus, it has been used in more than 80,000 treatments as an approved treatment of cytokine storm in the European Union and distributed in 58 countries around the world, where it has helped physicians control severe inflammation while helping to reverse shock, and improve respiratory and other organ function. And again, these complications are often the real reason patients die of COVID-19 infection.
Over the past two weeks, multiple patients with at least respiratory failure, shock, or kidney failure, in multiple hospitals in Wuhan, China have been treated with CytoSorb. Based on preliminary positive feedback on patient outcomes, we have responded to a request for additional devices and have now delivered a second shipment of CytoSorb devices to our partner in China, intended for new critically-ill COVID-19 patients.
In addition, we have learned of the first initial treatments of CytoSorb on COVID-19 patients in intensive care units in Italy. Though challenging to get feedback on how these patients have done, due to the overwhelming workload of the treating physicians, we hope to have more information soon. Meanwhile, we have also received an additional order from Iran, another country where coronavirus infection has been rapidly spreading.
Oddly in Germany, where CytoSorb has the greatest potential for COVID-19 treatment experience, the cases of coronavirus infection have been relatively mild, with Germany reporting more than 1,600 cases and only 3 deaths (0.2% mortality). This is in stark contrast to the U.S. with 1,257 cases and 38 deaths (3.0% mortality), and France, with 2,281 cases and 48 deaths (2.1% mortality). That said, German Chancellor Angela Merkel has warned that 60-70% of the population may get infected. Unfortunately, the reality is that there will be many opportunities to build treatment experience with CytoSorb in COVID-19 infection, not just in Germany, but wherever we sell CytoSorb.
There has been much discussion about the development of vaccines and anti-viral drugs for COVID-19. Unfortunately, a vaccine is not expected to be available until 12-18 months from now, far too late to impact the pandemic today. We welcome and applaud efforts to rapidly develop and evaluate anti-viral drugs that have activity against COVID-19, as these have the ability to reduce the severity of illness and potentially reduce the likelihood of an infected patient transmitting the virus to others. CytoSorb would work in synergy with these medications. That said, vaccines and anti-virals are not the full answer, as they do not treat the deadly complications of COVID-19 infection, as highlighted above. Seasonal influenza is just one example of this. Vaccines and anti-viral medications are readily available and used for the prevention and treatment of influenza, yet this season according to the Centers for Disease Control and Prevention (CDC), influenza was responsible for an estimated 34 million infections in the U.S., with 350,000 hospitalizations, resulting in 20,000 deaths – most of which were due to the complications of influenza infection that are nearly identical to those in COVID-19 infection.
Given the asymptomatic spread of COVID-19, the current lack of a vaccine and anti-viral therapies, and the fact the world population has no specific immunity to COVID-19, this pandemic has the potential to be devastating, causing a significant loss of life globally. Our goal is to make physicians aware of CytoSorb as a potential treatment option to help treat patients suffering from these deadly complications of severe COVID-19 infection, with the goal of speeding recovery, reducing the burden on ICUs, and saving lives.







COVID-19 pneumonia: what has CT taught us?
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30134-1/fulltext